P&G Pharmaceuticals Plans Job Cuts
P&G Pharmaceuticals Plans Job Cuts
Procter & Gamble Pharmaceuticals, the pharmaceutical unit of Procter & Gamble Company (Cincinnati, OH, www.pg.com), will cut some 300 jobs this summer as part of an overall strategy to focus on in-licensing and acquisition of late-stage compounds and to reduce its internal drug R&D operations.
The majority of the cuts will come from P&G’s Health Care Research Center in Mason, Ohio, with some cuts at facilities in New York, London, and Toronto. The Mason research center employs 2560 people. P&G will decide which positions will be eliminated by June 30. The reductions will include scientists, researchers, and other technical positions.
P&G will put into place a new licensing and acquisition structure by the end of June. The new group will target drugs in Phase II development or later with a focus on three therapeutic areas: muscular–skeletal drugs, women's health products, and gastrointestinal drugs.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
